medical professional with stethoscope around neck

Translating Scientific Discoveries into Patient Therapies

One of only a select number of programs worldwide to serve as a Clinical Center for TrialNet, a National Institutes of Health and JDRF sponsored research consortium charged with developing preventive therapies for diabetes, our team of experts conceptualize, design, and execute trials related to all aspects of type 1 diabetes.

For more information on participating in a clinical trial, call 844-813-8273 (844-T1D-UCSF) or contact us below.


Online Screener


Email Us



Current Studies

Precision Genetics for Type 1 Diabetes (w/ U Chicago)

In partnership with University of Chicago, we are looking for people who have T1D and other features that suggest a strong underlying genetic cause to their disease:

  • Families with two or more people with T1D, with or without other immune disorders
  • Individuals with T1D and multiple other autoimmune or inflammatory conditions. Examples of other conditions may include (but are not limited to):
    • Rheumatoid arthritis; Systemic lupus erythematosus (Lupus); Inflammatory bowel disease (IBD); Multiple sclerosis (MS); Psoriasis; Guillain-Barre syndrome; Vitiligo; Hypo- or hyperthyroidism; Mixed connective tissue disease


TrialNet Pathway to Prevention Study: for Family Members of relatives with Type 1

  • Ages 2 ½ - 45: 1st degree relatives 2 ½ - 45, 2nd and 3rd degree relatives 2 ½ - 20
  • Initial screening for type 1 diabetes antibodies
  • Participants who are antibody positive can participate in monitoring, and may be eligible for prevention studies


Hydroxychloroquine Prevention Study: HCQ for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus

  • Ages 3 and up
  • For people with 2 or more antibodies and normal glucose tolerance, determined by participating in TrialNet screening and monitoring
  • Oral medication taken at home
  • 2:1 Treatment/Placebo


PROTECT: Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

  • 8-17 yr olds
  • 12 consecutive days of Teplizumab infusions at Baseline and again at 6 months
  • Baseline first infusion within 42 days of diagnosis
  • 2:1 Treatment/Placebo


TOPPLE T1D: A multiple ascending dose trial investigating safety, tolerability and pharmacokinetics of NNC0361-0041 administered subcutaneously to patients with type 1 diabetes mellitus

  • Phase I Study for adults 18-45
  • Recombinant supercoiled plasmid encoding four human proteins: (preproinsulin (PPI), transforming growth factor β1 (TGF-β1), interleukin-10 (IL-10), and interleukin-2 (IL-2)
  • 4 Cohorts, with increasing dosage
  • 3:1 Treatment/Placebo
  • Weekly subcutaneous injections for 12 weeks
  • 48 hr inpatient stay for first dose, all other visits are outpatient